Tomosynthesis screening shows lower interval cancer rate than mammography

The TOSYMA trial compared invasive interval breast cancer rates in women aged 50-70 screened with digital breast tomosynthesis plus synthesised mammography versus digital mammography alone. The trial reported 14.2 interval cancers per 10,000 screened in the tomosynthesis group versus 18.6 per 10,000 in the digital mammography group over 24 months, a difference that did not reach statistical significance (adjusted OR 0.76, 95% CI 0.55-1.06). The trial authors stated this large randomised study adds substantial evidence supporting use of digital breast tomosynthesis plus synthesised mammography in breast cancer screening, noting about a quarter of interval cancers with digital mammography might be avoided with the combined approach.

Most relevant for: Women aged 50-70 undergoing routine breast cancer screening.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.